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Background: Impaired brain glucose metabolism appears to be a potential pathogenic feature of mild cognitive
impairment (MCI). This study examined the potential for increasing circulating ketone bodies through medium
chain triglyceride (MCT) supplementation, as a means to beneﬁcially modulate brain homeostasis in subjects
with MCI.
Methods: Six participants with MCI were enrolled in a randomized placebo-controlled trial. Participants received
56 g/day of either medium chain triglycerides (MCTs) or placebo for 24 weeks. Serum β-hydroxybutyrate con-
centrations, apolipoprotein-E4 status, and cognitive assessments were carried out. Due to the small number of
participants only the raw scores were examined.
Results: Intake of MCT oil increased serum ketone bodies and improvedmemory, while intake of placebo did not
show improvement in any of the cognitive measures tested.
Conclusions: Consumption of 56 g/day of MCTs for 24weeks increases serum ketone concentrations and appears
to be a candidate for larger randomized control trials in the future that quantify themodulation of cognitive func-
tion through supplementation with ketone precursors, in patients with MCI.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD) is the result of slow progressive neurode-
generative changes that develop in the brain and is initially character-
ized by selective impairments of the cognitive domains related to
learning and memory [1]. Apolipoprotein E ε4 allele (ApoE4) increases
the risk of AD by three times in heterozygotes and by 15 times in homo-
zygotes [2]. The presence of cognitive impairment that is not sufﬁcient
to affect social function or activities of daily living is generally referred
to asmild cognitive impairment (MCI), withMCI being generally recog-
nized as one of the earliest stages of AD.
Several pathogenic mechanisms that underlie the changes observed
in AD have been proposed, and an emerging body of evidence points to
signiﬁcantly lower brain glucose metabolism as being a general featuresearch Center, Louisiana State
808, United States. Tel.: +1 225
way).
. This is an open access article underof ADwhich precedes cognitive dysfunction and pathological alterations
[3]. It has been hypothesized that perturbations in cell energy metabo-
lism cause the clinical and histologic changes observe in AD [4].
There is increasing evidence of a functional response leading to im-
proved brain function in response to the consumption of nutritional
supplements that increase energy sources in the brain, especially, the el-
evation of ketones [5,6]. This study evaluated the effect of the daily con-
sumption of an oil, composed of medium chain triglycerides (MCTs) for
24 weeks on serum ketone body concentrations (β-hydroxybutyrate
[BHB]) and cognitive performance assessed by the Alzheimer's Disease
Assessment Scale-Cognitive subscale (ADAS-Cog), Trail Making Test,
and Digit Symbol Test, in MCI subjects.
2. Study design and methods
Six individuals ≥50 years, with MCI were enrolled in a pilot and
feasibility, randomized double blind placebo-controlled parallel trial.
MCI was deﬁned using the 2011 National Institute on Aging and
Alzheimer's Association work group [7] and related clinical guidelines.
Brieﬂy, diagnosis was made on: (1) identiﬁcation of a concern forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS [Cog]) scores from base-
line to week 24.
Memory Language Praxis Overall ADAS (Cog)
Test
ApoE4(−) 4 1 0 5 Week 0
10 0 0 10 Week 24
ApoE4(+) 9 1 1 18 Week 0
12 0 2 14a Week 24
Placebo
Subject 1 6 0 1 7 Week 0
5 0 1 7 Week 24
Subject 2 14 2 1 17 Week 0
8 2 1 13 Week 24
a Decline in orientation reduced the overall ADAS (Cog).
Table 2
Serum β-hydroxybutyrate concentrations before and after eating yogurt containingmedi-
um chain triglyceride oil.
Week 0 mM Week 4 mM Week 24 mM
Test
ApoE4(−) 0.19 0.02 0.01 Fasting
0.64 0.26 0.15 Post-prandial
ApoE4(+) 0.06 0.26 0.13 Fasting
0.32 0.39 0.54 Post-prandial
Placebo
Subject 1 0.04 0.08 0.06 Fasting
0.01 0.03 0.02 Post-prandial
Subject 2 0.04 0.02 0.03 Fasting
0.04 0.03 0.03 Post-prandial
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orated by care giver), (2)minimental state examination score of 25–28,
(3) preservation in independence of functional abilities, and (4) lack of
dementia (signiﬁcant impairment of social or occupational function-
ing). Subjects were excluded if they had major depression as deter-
mined by the Geriatric Scale for Depression in Dementia score ≥ 6,
were on medication for MCI less than 90 days, and had uncontrolled
hypothyroidism, B12 deﬁciency, or clinically signiﬁcant hepatic disease
or insufﬁciency. The study was approved by the Institutional Review
Board of Pennington Biomedical Research Center, where the study
was conducted, and records maintained. Subjects recruited from Baton
Rouge and the surrounding areas provided written informed consent.
The trial was registered on ClinicaTrials.gov (NCT01669200).
Psychological testing which included the ADAS (Cog), Trail making,
and Digit Symbol tests was done just prior to the baseline visit. Subjects
reported for the baseline visit fasting from 9 p.m. the prior night, and
blood was drawn for ApoE4 status, serum BHB, blood glucose and insu-
lin. Subjects then consumed 56 g ofMCT's (MCToil, Nestle™) or placebo
(canola oil, colormatched) added to six ounces of Yoplait™ 99% fat-free
fruit yogurt. Randomization was conducted by the study pharmacist
using a randomnumber table andwas revealed to study staff and inves-
tigators only at the conclusion of the study. Blood was drawn 90 min
later to assess post-prandial serum BHB. In addition, subjects' diet was
assessed by a registereddietitian and they received instruction on incor-
poration of the study products into the diet. Study products were
dispensed at each visit in excess of requirements, and re-issued at
every visit. Returned product was measured to assess compliance.
The post-baseline visits atweeks 4, 8, 12, 16, and20 included dispen-
sation of study products, compliance assessment, and instruction by a
registered dietitian. In addition, at week 4, baseline blood testing for
glucose, insulin, and pre/post-prandial BHB were repeated. At week
24, the clinical tests except ApoE4 status, and the psychological tests
done at baseline were repeated. Subjects were asked about adverse
events at all post-baseline visits. Weight and vital signs were measured
at all visits.
2.1. Statistical analyses
Twenty subjects were to be randomized to two groups of ten each;
however, the trial concluded after six subjects were enrolled due to a
preference among them for enrolling in other MCI studies, including
drug trials. Since only four subjects completed the study there was
insufﬁcient data for assessing statistical signiﬁcance in the differences
between the two groups. Therefore, the raw scores were examined.
3. Results
Subjects ranging in age from 58 to 78 years were enrolled and
followed from October 2012 to August 2013. One subject with a history
of gastrointestinal dysfunction dropped out due to a recurrence of these
events and one subject was dropped due to non-compliance. There
were no other adverse events. Two of the remaining subjects received
MCT oil (one male, one female) and two received the placebo (one
male, one female). Subjects were able to easily incorporate the MCT
oil into their diet, without changes in their usual intake or weight gain.
Of the two subjects who received the MCT oil, one had ApoE4
negative status, andmemory performance as measured by thememory
subtests of theADAS-COG (word recall, word recognition, remembering
test instruction) increased from baseline to week 24. No improvements
in language or praxis of the ADAS-COGwere observed in this individual.
Consequently, there was an increase in the overall ADAS (Cog) score in
this individual. In the second participant who was homozygous for
ApoE4, memory performance as measured by word recall, word recog-
nition, remembering test instruction also improved from baseline to
week 24, but a decline in orientation led to a decrease in overall ADAS
(Cog) scores (Table 1). Therewere no improvements in the TrailMakingTest, and Digit Symbol Test. Post-prandial BHB concentrations increased
in the subject with negative ApoE4 status at baseline, but the increase in
post-prandial BHBwas progressively less when the tests were repeated
atweek four andweek 24. In the participant with positive ApoE4 status,
there was a consistent increase in post-prandial serum BHB from base-
line to week 24 (Table 2). Blood glucose and insulin concentrations
were in the normal range. Subjects in the placebo group showed no
improvement in memory or overall ADAS (Cog) scores (Table 1).
4. Discussion
SupplementationwithMCT oil for 24weeks increased post-prandial
serum BHB concentrations and improvedmemory in a participant with
negative ApoE4 status, and to a lesser extent in a participant with
positive ApoE4 status. In the subject with ApoE4 positive status,
the post-prandial BHB concentrations progressively increased over the
course of the study. However, the increase in post-prandial BHB in the
participant with ApoE4 negative status progressively lessened over
the course of the study suggesting an adaptation whereby ketones
were used at an increased rate as an energy source.
When consumed in sufﬁciently large quantities MCTs promote the
generation of ketone bodies from excess acetyl-CoA. Ketone bodies are
transported across the blood brain barrier for oxidative metabolism by
neuronal mitochondria, and serve as an energy source. However, the
adult brain does not usually metabolize ketone bodies unless uptake
of glucose in the brain is reduced [8]. Cerebral glucose metabolism is
therefore dependent upon both glucose transportation and the rates
of intracellular oxidative catabolism, with ketone bodies potentially
serving as an auxiliary energy source when glucose concentrations are
reduced [1].
Positron emission topography (PET) using F-ﬂuorodeoxyglucose
(FDG) as a tracer shows that AD is characterized by reductions in
cerebral glucose metabolism in the parietal, temporal, and frontal
lobes [9,10] which are preceded by hypometabolism in memory-
related regions such as the hippocampal structures [11]. Patients with
125C.J. Rebello et al. / BBA Clinical 3 (2015) 123–125MCI suffer isolated memory damage. Previous evidence from FDG-PET
scans indicates that there is an apparent decrease in glucosemetabolism
in hippocampal structures in MCI [12]. The expression of glucose trans-
porters Glut-1 and Glut-3, which play a key role in modulation of brain
glucose transportation, is also decreased in AD patients [13]. Physiolog-
ically, ketone bodies are a potential replacement fuel for the brain en-
abling the preservation of brain function during periods of low glucose
availability. Moreover, the brain has a transport system for ketones
that is independent of glucose transport [3].
In a study investigating the effects of a single 40 ml dose of MCT oil
an elevation of serum BHB to 0.5 mM was induced after two hours
and led to a signiﬁcant correlationwith performance on a paragraph re-
call test in the overall sample. Further, subjects lacking the ApoE4 gene
variant also showed signiﬁcant improvements in the ADAS (Cog) [5]. In
another study, daily consumption of 20 g of MCTs resulted in signiﬁcant
improvement in cognitive effects in subjects lacking the ApoE4 gene
variant, at the end of 90 days. However, the cognitive effects were not
signiﬁcant in the overall sample [6]. Placing subjects with MCI on a
low carbohydrate diet to induce ketosis has also been shown to improve
memory [14].
In the present study, MCT oil intake induced an increase in BHB con-
centrations and led to an improvement inmemory in subjects withMCI.
The study is limited in that it was not possible to show statistical signif-
icance due to the small number; however, based on the estimate of
effect size provided by this study a power analysis showed that 16
subjects in each group are needed to provide 80% power to detect differ-
ences in the improvement in memory. The calculations assume a t-test
for comparing means of two independent samples with α= 0.05, to
test equality of mean change score against a two-directional alternative
of unequal change.
Approved drugs only treat the symptoms of the disease and drug
trials focusing on a single mechanism do not seem to have had much
success. Alzheimer's disease is a multifactorial disease, but, a common
feature ofmany systemic processes linked to AD is involvement in ener-
gymetabolism [15]. Anecdotal evidence indicates thatMCTs as part of a
comprehensive therapeutic system are effective in reversing cognitive
decline [16]. It is likely that targetingmultiple aspects of the pathophys-
iology may prove successful in treating AD; however, optimizing the
therapeutics of each of these targets is of paramount importance [16].
5. Conclusions
Intake of MCT oil for 24 weeks increases serum post-prandial BHB
concentrations and improvesmemory in patients withMCI. At a plasma
concentration of 1.5 mM, 18% of the brain's energy needs which is the
deﬁcit observed in MCI, can be met [3,17]. However, palatable more
readily convertible forms of BHB or keto-esters may be a more effective
treatment.
6. General signiﬁcance
Improvement in memory through supplementation with MCT oil
offers support to the hypothesis that ketones counteract the effects of
impaired cerebral energy metabolism.Transparency document
The Transparency document associated with this article can be
found, in the online version.
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